Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Hutchmed China Ltd on Tuesday reported it was granted conditional approval in China for an injection to treat endomet ...
Hutchmed (China) Limited 29 November 2024 Total Voting Rights Hong Kong, Shanghai & Florham Park, NJ - Friday, November 29, 2024: HUTCHMED (China) Limited ("HUTCHMED...
Hutchmed (China) Ltd on Friday said it will receive a milestone payment from Takeda Pharmaceutical Co Ltd after Taked ...
Hutchmed (China) Limited 20 November 2024 HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee Hong Kong, Shanghai & Florham Park, NJ...
Hutchmed (China) Ltd on Thursday said it will receive a USD20 million payment from its partner Takeda Pharmaceutical ...
Hutchmed (China) Limited 31 October 2024 Total Voting Rights Hong Kong, Shanghai, & Florham Park, NJ – Thursday, October 31, 2024: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:...
Hutchmed (China) Limited 21 October 2024 Vesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ - Monday, October 21, 2024: HUTCHMED (China) Limited...
Hutchmed China Ltd on Wednesday said that Tagrisso plus Orpathys showed a high clinically meaningful response rate in ...
Hutchmed (China) Limited 16 October 2024 HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of...
Takeda Pharmaceutical Co Ltd on Tuesday said it landed an approval for its Fruzaqla drug in Japan. The drug has bee ...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 5 | 1.82481751825 | 274 | 300 | 266 | 48714 | 282.55330339 | DE |
| 4 | -5 | -1.76056338028 | 284 | 300 | 260 | 51026 | 278.97223681 | DE |
| 12 | 28 | 11.1553784861 | 251 | 336 | 242 | 137266 | 296.48113766 | DE |
| 26 | -13 | -4.45205479452 | 292 | 336 | 242 | 100260 | 294.00678605 | DE |
| 52 | -9 | -3.125 | 288 | 353 | 190.4 | 85515 | 286.70901034 | DE |
| 156 | -232 | -45.4011741683 | 511 | 541 | 130 | 102419 | 265.88015121 | DE |
| 260 | -87 | -23.7704918033 | 366 | 656 | 130 | 101384 | 348.57078539 | DE |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
